Oncology News

The addition of lenvatinib and pembrolizumab to transarterial chemoembolization extended PFS for patients with intermediate-stage hepatocellular carcinoma, according to randomized phase 3 study results.

The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection.

Women with hepatocellular carcinoma were less likely to receive a liver transplant and more likely to die or be removed from the waitlist vs. men, underscoring the need for changes to allocation policies, according to researchers.

Neoadjuvant immunotherapy may allow more people with hepatocellular carcinoma to undergo surgical resection, according to retrospective study results.

A model using both clinical and imaging data predicted the absence of high-risk varices in patients with unresectable hepatocellular carcinoma and may help avoid unnecessary upper endoscopy in low-risk patients, research showed.

A prediction model could be a “starting point” to identify patients with metabolic dysfunction-associated steatotic liver disease at high risk for hepatocellular carcinoma who may require intervention or surveillance, researchers wrote.

A continuous risk score accurately predicted waitlist dropout and post-liver transplantation outcomes in patients with hepatocellular carcinoma, even over the course of several UNOS policy changes, researchers reported.

Hepatocellular carcinoma screening in at-risk patients was linked to reduced mortality after accounting for lead-time and length-time biases, as well as improved early tumor detection and treatment, according to data in JAMA Network Open.

Around 17% of patients with metabolic dysfunction-associated steatotic liver disease have or will be diagnosed with alcohol-related disease, which research shows is associated with a threefold higher rate of developing cirrhosis or cancer.